# Liang Lin

> Liang Lin is the Chinese founder and CEO of Sol-Millennium Medical Group and the executive chairman and CEO of NuGen Medical Devices. From a medical-device project launched in Shanghai, he developed a business with manufacturing, research, sales and distribution activity across several regions, then moved into publicly listed needle-free drug delivery through a strategic investment in NuGen. His public record is sparse but unusually concrete: acquisitions in North and South America, an R&D center in Switzerland, a Chicago headquarters, a 2016 WHO injection-safety meeting, and a 2025-2026 program of new platforms and patent filings at NuGen.

- **Role:** Founder and CEO of Sol-Millennium Medical Group; Executive Chairman, CEO and Director of NuGen Medical Devices Inc.
- **Organizations:** Sol-Millennium Medical Group, Sol-Millennium Medical Inc., NuGen Medical Devices Inc.
- **Nationality:** Chinese
- **Education:** Royal Holloway, University of London
- **Known for:** Founded and scaled Sol-Millennium Medical Group from a Shanghai project into a medical-device organization with operations and offices across Asia, North America, South America and Europe., Led the acquisitions that brought Sol-Millennium into the North American and Brazilian markets., Established Sol-Millennium's dedicated Swiss R&D center and later relocated the group's global headquarters to Chicago.

## Career timeline

- **2007** — Launched the Sol-Millennium medical-device project in Shanghai and became the group's founder and CEO.
- **2009** — Led Sol-Millennium's expansion into North America and Brazil through the acquisitions of Inviro Medical Inc. and Medica Brazil; the company also established an EMEA office in Poland.
- **2015** — Sol-Millennium opened a dedicated R&D center in Switzerland and introduced new safety-needle and blood-collection products.
- **2016** — Represented Sol-Millennium Group at the first WHO private-organizations meeting on injection safety in Geneva.
- **2019** — Sol-Millennium moved its global corporate headquarters to Chicago.
- **2021** — Became the disclosed person with significant control of Sol-Millennium UK Limited, with at least 75% of shares and voting rights.
- **2024-09** — Joined NuGen Medical Devices as a director and executive chairman when Sol-Millennium and Nature Health closed a C$10 million secured convertible-debenture financing.
- **2025-01** — Appointed chief executive officer of NuGen Medical Devices while remaining founder and CEO of Sol-Millennium Medical Group.
- **2025-12** — The FDA issued a closeout letter stating that Sol-Millennium appeared to have addressed violations cited in a March 2024 warning letter, while noting that future inspections would test the sustainability of the corrections.
- **2026** — NuGen filed patent applications for a prefilled nozzle, dual-spring pressure control, spring charging and automatic dose-setting technologies under Lin's leadership.
- **2026-09** — A Lin-controlled Sol-Millennium entity entered a loan agreement of up to C$1.3 million with NuGen in connection with a proposed acquisition of Sol-Millennium Canada; Lin disclosed his conflict and abstained from board deliberations.

## Achievements

- Founded and scaled Sol-Millennium Medical Group from a Shanghai project into a medical-device organization with operations and offices across Asia, North America, South America and Europe.
- Led the acquisitions that brought Sol-Millennium into the North American and Brazilian markets.
- Established Sol-Millennium's dedicated Swiss R&D center and later relocated the group's global headquarters to Chicago.
- Participated in the WHO's 2016 private-organizations meeting on injection safety in Geneva.
- Became executive chairman and then CEO of publicly traded NuGen Medical Devices following Sol-Millennium's strategic investment.
- Directed NuGen's expansion of its patent pipeline into transfer, refill and prefilled needle-free delivery platforms.

## Latest updates

- **2026-09** — A Lin-controlled Sol-Millennium entity agreed to lend NuGen up to C$1.3 million, with the later tranche tied to a proposed acquisition of Sol-Millennium Canada.
- **2026-08** — NuGen signed a non-binding letter of intent to acquire Sol-Millennium Canada in a proposed share transaction that would leave Sol-Millennium Medical HK with about 65% of NuGen after closing.
- **2026-07** — NuGen filed two more patent applications covering spring-charging and automatic dose-establishment technology for future needle-free platforms.
- **2026-05** — NuGen filed a patent application for dual-spring technology intended to shape the pressure profile of a needle-free injection.
- **2026-03** — NuGen filed a patent application covering parts of a ready-to-fill prefilled-nozzle platform.

## Links

- Website: https://solm.com
- LinkedIn: https://www.linkedin.com/in/%E4%BA%AE-%E6%9E%97-07764297

---

Profile page: https://yespress.io/liang-lin
Published by YesPress — https://yespress.io
Last updated: 2026-09-27